Wugen
wugen.comLocations
St. Louis, MO, USA
industry
Biotechnology · DeepTech · Health
Size
51-200 employees
Stage
Series B
founded in
2018
Wugen is developing off-the-shelf cellular therapies for cancer. Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and T-cell malignancies.
Something looks off?Open jobs at Wugen
On-site & Remote
Seniority
Salary